Resources

Editor’s Note: There is no doubt that the improved access to high quality, virtual care in the post COVID era has provided numerous benefits for patients. Many patients that were previously unable to access specialty care in remote areas can now receive treatment conveniently. Individuals with chronic conditions such as diabetes can share their physiological data with providers to monitor their chronic conditions

Pharmacies can significantly impact pharmaceutical manufacturers’ commercial success as crucial players in the prescription fulfillment process. In addition to playing an essential role in the supply chain, pharmacies are the only consumer-facing entities. An ineffective distribution network can diminish a brand’s reputation, patient and provider satisfaction, health outcomes, and gross to net

Editor’s Note: As the Biotech industry faces unprecedented levels of uncertainty in the midst of a trying macroeconomic environment, it’s more critical than ever for commercial stage innovators to deploy effective go-to-market strategies that generate sustainable brand growth. Sustainable growth strategies are those that maximize adoption (amongst patients & HCPs) while also protecting gross-to-net by avoiding free good overutilization. Such strategies can extend cash runways, provide a positive story for investors, and can even position biotechs for a successful acquisition

As life science companies continue to invest in and launch specialty and specialty-lite medications to help patients manage chronic - and sometimes debilitating or life threatening - conditions, they are tasked with developing patient support services programs to help patients access and stay on these therapies. Unfortunately, a poorly utilized program can undermine clinical efficacy and often hinders a brand’s commercial success. Despite pouring $5 billion each year into patient support programs, pharmaceutical manufacturers only get an estimated 3 percent of eligible patients to enroll and use their programs

Editor’s Note: With the lion’s share of R&D investment in the pharmaceutical industry flowing into specialty medications that command high list prices, insurers continue to search for new avenues to reign in prescription drug spending. Aside from enacting utilization requirements that often contribute to significant barriers to patient access, many payers are exploring value-based contracts with life sciences manufacturers that pay based on the positive health outcomes that therapies deliver for patients. The logic is that manufacturers should not pay for therapies that are not efficacious for an individual's health